ABCG2 mRNA expression in plasma cells from subjects enrolled in the MTV trial
. | . | ABCG2 mRNA expression/cell* . | . | . | . | ||
---|---|---|---|---|---|---|---|
Paired sample . | n . | Before HDC . | During HDC . | Relapse from HDC . | P† . | ||
Before HDC versus during HDC | |||||||
Dose level 1 | 6 | 29.3 | 48.2 | NA | .56 | ||
Dose levels 2 to 5 | 20 | 118.4 | 232.5 | NA | .033 | ||
Before HDC versus relapsed from HDC | |||||||
Dose level 1 | 5 | 26.6 | NA | 17.6 | .999 | ||
Dose levels 2 to 5 | 11 | 31.7 | NA | 117.1 | .001 |
. | . | ABCG2 mRNA expression/cell* . | . | . | . | ||
---|---|---|---|---|---|---|---|
Paired sample . | n . | Before HDC . | During HDC . | Relapse from HDC . | P† . | ||
Before HDC versus during HDC | |||||||
Dose level 1 | 6 | 29.3 | 48.2 | NA | .56 | ||
Dose levels 2 to 5 | 20 | 118.4 | 232.5 | NA | .033 | ||
Before HDC versus relapsed from HDC | |||||||
Dose level 1 | 5 | 26.6 | NA | 17.6 | .999 | ||
Dose levels 2 to 5 | 11 | 31.7 | NA | 117.1 | .001 |